Prevalence and Molecular Identification of Human Schistosomiasis
ConditionSchistosomiasis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAssiut University
About this trial
Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.
Patients clinically suspected of having schistosomiasis (urinary and/or intestinal) or referred for parasitological examination.
Individuals (or guardians, in case of minors) who provide written informed consent.
Patients willing to provide the required biological samples (urine and/or stool).
Disqualifiers
Patients Received praziquantel within the last 3 months before sample collection
Patients with incomplete clinical or epidemiological data.
Patients refusing participation or sample collection.
Improperly collected, contaminated, or insufficient samples.
Trial population
All participants presented in Assiut Governorate hospitals
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Molecular phylogenetic and haplotype analysis
Diagnostic testDNA Sequencing and cox1 Gene Analysis of Schistosoma Isolates
Treatment groups
359 Participants
are divided into 2 treatment groupsGroup A: Schistosoma haematobium1 intervention
Group B: Schistosoma mansoni1 intervention
Trial outcomes
Primary outcomes
1
prevalence of human schistosomiasis in the study participants
using conventional microscopic examination
Time frame
24 hoursLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: